The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is a huge mover today! The stock increased 7.03% or $24 during the last trading session, hitting $365.39. About 1.34M shares traded hands or 85.88% up from the average. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has declined 15.42% since April 5, 2016 and is downtrending. It has underperformed by 17.38% the S&P500.
The move comes after 8 months positive chart setup for the $38.32B company. It was reported on Nov, 7 by Barchart.com. We have $559.05 PT which if reached, will make NASDAQ:REGN worth $20.31 billion more.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Ratings Coverage
Out of 19 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 9 rate it a “Buy”, 1 “Sell”, while 9 “Hold”. This means 47% are positive. Regeneron Pharmaceuticals Inc. has been the topic of 41 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The rating was maintained by RBC Capital Markets with “Buy” on Monday, August 31. Leerink Swann maintained it with “Outperform” rating and $523 target price in Monday, April 4 report. Roth Capital upgraded the shares of REGN in a report on Tuesday, January 19 to “Buy” rating. As per Tuesday, March 15, the company rating was initiated by Gabelli. The company was maintained on Monday, April 4 by Roth Capital. Chardan Capital Markets upgraded the shares of REGN in a report on Tuesday, February 16 to “Neutral” rating. The stock has “Hold” rating given by Zacks on Tuesday, August 11. Credit Suisse initiated the shares of REGN in a report on Wednesday, January 20 with “Neutral” rating. Canaccord Genuity downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Wednesday, January 27 to “Hold” rating. Leerink Swann initiated the stock with “Outperform” rating in Friday, February 5 report.
According to Zacks Investment Research, “Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron’s platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)”
Insitutional Activity: The institutional sentiment increased to 1.19 in 2016 Q2. Its up 0.44, from 0.75 in 2016Q1. The ratio increased, as 51 funds sold all Regeneron Pharmaceuticals Inc shares owned while 154 reduced positions. 50 funds bought stakes while 193 increased positions. They now own 70.88 million shares or 9.49% less from 78.30 million shares in 2016Q1.
The Oregon-based Oregon Employees Retirement Fund has invested 0.06% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Art Advsr Ltd reported 13,088 shares or 0.23% of all its holdings. Cambridge Inv Research Advsr last reported 2,747 shares in the company. Public Sector Pension Invest Board, a Quebec – Canada-based fund reported 14,797 shares. Old Mutual Investors (Uk) Limited has invested 0.73% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Moreover, National Asset Mgmt Inc has 0.08% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 1,109 shares. Advisor Prns Ltd Liability Corporation has 861 shares for 0.11% of their US portfolio. Capstone Inv Advsr Limited owns 10,303 shares or 0.07% of their US portfolio. Yorktown Mgmt Co Inc holds 0.06% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 700 shares. Cubist Systematic Strategies Lc, a Connecticut-based fund reported 7,054 shares. Twin Tree Mngmt Lp holds 4,781 shares or 0.03% of its portfolio. Vanguard Group reported 4.78M shares or 0.1% of all its holdings. Sumitomo Life Insurance holds 3,389 shares or 0.16% of its portfolio. Endurance Wealth Mngmt holds 0% or 30 shares in its portfolio. Valley Advisers holds 0% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 15 shares.
Insider Transactions: Since May 17, 2016, the stock had 1 buying transaction, and 3 selling transactions for $20.55 million net activity. Shares for $396,640 were sold by RYAN ARTHUR F on Tuesday, May 24. On Friday, July 29 GOLDSTEIN JOSEPH L sold $903,125 worth of the stock or 2,125 shares. Sanofi bought $23.55M worth of stock or 64,731 shares. Van Plew Daniel P had sold 4,413 shares worth $1.70M.
More recent Regeneron Pharmaceuticals Inc (NASDAQ:REGN) news were published by: Fool.com which released: “Better Buy: Regeneron Pharmaceuticals, Inc. vs. Roche Holding AG” on October 13, 2016. Also Fool.com published the news titled: “Is Another Blockbuster Drug on the Way for Regeneron Pharmaceuticals, Inc.?” on October 10, 2016. Prnewswire.com‘s news article titled: “Science Magazine Once Again Names Regeneron the Best Company to Work For” with publication date: October 27, 2016 was also an interesting one.
REGN Company Profile
Regeneron Pharmaceuticals, Inc., incorporated on January 11, 1988, is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. The Firm commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. The Company’s marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. The Firm has over 10 product candidates in clinical development. These consist of Trap clinical programs and over 10 human monoclonal antibody product candidates. The Firm has generated each of the antibodies using its VelocImmune technology. The Company’s ARCALYST (rilonacept) Injection for subcutaneous Use is available in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children over 12 year.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.